A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/314435

Lähdeviite

Salminen , L , Nadeem , N , Jain , S , Grènman , S , Carpén , O , Hietanen , S , Oksa , S , Lamminmäki , U , Pettersson , K , Gidwani , K , Huhtinen , K & Hynninen , J 2020 , ' A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer ' , Gynecologic Oncology , vol. 156 , no. 3 , pp. 689-694 . https://doi.org/10.1016/j.ygyno.2019.12.025

Julkaisun nimi: A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer
Tekijä: Salminen, Liina; Nadeem, Nimrah; Jain, Shruti; Grènman, Seija; Carpén, Olli; Hietanen, Sakari; Oksa, Sinikka; Lamminmäki, Urpo; Pettersson, Kim; Gidwani, Kamlesh; Huhtinen, Kaisa; Hynninen, Johanna
Tekijän organisaatio: HUSLAB
Precision Cancer Pathology
Department of Pathology
Helsinki University Hospital Area
University of Helsinki
Research Programs Unit
Päiväys: 2020-03
Kieli: eng
Sivumäärä: 6
Kuuluu julkaisusarjaan: Gynecologic Oncology
ISSN: 0090-8258
DOI-tunniste: https://doi.org/10.1016/j.ygyno.2019.12.025
URI: http://hdl.handle.net/10138/314435
Tiivistelmä: Objective. Cancer antigen 125 (CM 25) is generally considered the gold standard of biomarkers in the diagnosis and monitoring of high grade serous ovarian carcinoma (HGSC). We recently reported, that two CM 25 glycoforms (CA125-STn and CA125-MGL) have a high specificity to HGSC and further hypothesized, that these cancer specific glycoforms are feasible candidates as biomarkers in HGSC treatment and follow up. Methods. Our cohort consisted of 122 patients diagnosed with HGSC. Serum samples were collected longitudinally at the time of diagnosis, during treatment and follow up. Serum levels of CA125, CM 25-STn and CA125MGL were determined and compared or correlated with different end points (tumor load assessed intraoperatively, residual disease, treatment response, progression free survival). Results. Serum CA125-STn levels at diagnosis differentiated patients with low tumor load and high tumor load (p = 0,030), indicating a favorable detection of tumor volume. Similarly, the CA125-STn levels at diagnosis were significantly lower in patients with subsequent complete cytoreduction than in patients with suboptimal cytoreduction (p = 0,025). Conventional CA125 did not differentiate these patients (p = 0,363 and p = 0,154). The CA125-STn nadir value predicted the progression free survival of patients. The detection of disease relapse was improved with CA125-STn, which presented higher fold increase in 80,0% of patients and earlier increase in 37,0% of patients. Conclusions. CA125-STn showed promise as a useful biomarker in the monitoring and follow up of patients with HGSC utilizing a robust and affordable technique. Our findings are topical as a suitable indicator of tumor load facilitates patient selection in an era of new targeted therapies. (C) 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
Avainsanat: 3122 Cancers
Ovarian cancer
High grade serous ovarian carcinoma
CA125
Glycoform
SURVIVAL
RECIST
CLINICAL-TRIALS
PREOPERATIVE SERUM CA-125
LEVEL
PROGRESSION
TUMOR CYTOREDUCTION
3123 Gynaecology and paediatrics
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: cc_by
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
1_s2.0_S0090825819318463_main.pdf 609.6KB PDF Avaa tiedosto
A_longitudinal_ ... _serous_ovarian_cancer.pdf 646.7KB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot